| Company Name: |
Alexion Pharmaceuticals,Inc. |
| Headquarters: |
Cheshire CT |
| Sector: |
Basic Materials |
|
|
 |
 Learn more about Alexion Pharmaceuticals, Inc. View All Alexion Pharmaceuticals, Inc. Opportunities |
|
| Alexion Pharmaceuticals, Inc. is a biopharmaceutical company working to develop and deliver life-changing drug therapies for patients with serious and life-threatening medical conditions. Employing more than 500 people worldwide, Alexion is engaged in the discovery, development and commercialization of therapeutic products aimed at treating patients with a wide array of severe disease states, including hematologic and kidney diseases, transplant, cancer, and autoimmune disorders. Soliris(R) (eculizumab) is Alexion's first marketed product for patients with paroxysmal nocturnal hemoglobinuria (PNH) a rare, debilitating and life-threatening blood disorder defined by the destruction of red blood cells, or hemolysis. Soliris is approved in the U.S. and Europe in 2007, and Canada and Australia in 2009. Alexion is evaluating other potential indications for Soliris as well as other formulations of eculizumab for additional clinical indications, and is pursuing development of other antibody product candidates in early stages of development. Further information about Alexion Pharmaceuticals, Inc. can be found at: www.alexionpharma.com. | | |
|
